Your browser doesn't support javascript.
loading
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.
Sommerhäuser, G; Kurreck, A; Stintzing, S; Heinemann, V; von Weikersthal, L Fischer; Dechow, T; Kaiser, F; Karthaus, M; Schwaner, I; Fuchs, M; König, A; Roderburg, C; Hoyer, I; Quante, M; Kiani, A; Fruehauf, S; Müller, L; Reinacher-Schick, A; Ettrich, T J; Stahler, A; Modest, D P.
Afiliación
  • Sommerhäuser G; Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kurreck A; Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Stintzing S; Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Heinemann V; German Cancer Consortium (DKTK), DKFZ, Heidelberg, Germany.
  • von Weikersthal LF; German Cancer Consortium (DKTK), DKFZ, Heidelberg, Germany.
  • Dechow T; Department of Hematology/Oncology, LMU Klinikum, University of Munich, Comprehensive Cancer Center Munich, Munich, Germany.
  • Kaiser F; Gesundheitszentrum St. Marien, Amberg, Germany.
  • Karthaus M; Oncological Practice, Ravensburg, Germany.
  • Schwaner I; Oncological Practice, Landshut, Germany.
  • Fuchs M; Department of Hematology and Oncology, Klinikum Neuperlach/ Klinikum Harlaching, Munich, Germany.
  • König A; Oncological Practice Kurfuerstendamm, Berlin, Germany.
  • Roderburg C; Department of Gastroenterology, Hepatology, and Gastrointestinal Oncology, München Klinik Bogenhausen, Munich, Germany.
  • Hoyer I; Department of Gastroenterology and Gastrointestinal Oncology Goettingen, University Medical Center Goettingen, Goettingen, Germany.
  • Quante M; Department of Gastroenterology, Hepatology, and Infectiology, University Medical Center Duesseldorf, Duesseldorf, Germany.
  • Kiani A; Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Fruehauf S; Department of Gastroenterology, Hepatology, Endocrinology, and Infectiology, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.
  • Müller L; Department of Medicine IV, Klinikum Bayreuth GmbH, Bayreuth, Germany.
  • Reinacher-Schick A; Department of Hematology, Oncology, and Palliative Care, Klinik Dr. Hancken GmbH, Stade, Germany.
  • Ettrich TJ; Onkologie UnterEms, Leer, Germany.
  • Stahler A; Department of Hematology, Oncology and Palliative Care, Ruhr-University Bochum, Bochum, Germany.
  • Modest DP; Department of Internal Medicine, University Hospital Ulm, Ulm, Germany.
BMC Cancer ; 22(1): 820, 2022 Jul 27.
Article en En | MEDLINE | ID: mdl-35897060
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Trifluridina Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Trifluridina Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Alemania